Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Determining the optimal fasting glucose target for patients with type 2 diabetes: Results of the multicentre, open-label, randomized-controlled FPG GOAL trial.
Yang W, Ma J, Yuan G, Li L, Zhang M, Lu Y, Ye X, Song W, Liu M, Wu J, Chen R, Li Y, Zhang X, Cui N, Yang J. Yang W, et al. Among authors: cui n. Diabetes Obes Metab. 2019 Aug;21(8):1973-1977. doi: 10.1111/dom.13733. Epub 2019 Jun 10. Diabetes Obes Metab. 2019. PMID: 30938035 Free PMC article. Clinical Trial.
Observational study evaluating the effectiveness of physician-targeted education for improving glycemic management of patients with type 2 diabetes (BEYOND II).
Weng J, Zhao J, Zhou Z, Guo X, Zou D, Ji Q, Tong N, Li Q, Zhu J, Li Q, Qin G, Feng P, Yang L, Gao Z, Chen L, Li H, Li Y, Zeng L, Zhu D, Lu J, Luo T, Cui N. Weng J, et al. Among authors: cui n. J Diabetes. 2020 Jan;12(1):66-76. doi: 10.1111/1753-0407.12963. Epub 2019 Aug 6. J Diabetes. 2020. PMID: 31222955 Free PMC article.
Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: Results of a multicentre, open-label, randomized controlled trial (BEYOND VII).
Ji L, Wan H, Wen B, Wang X, Wang J, Bian R, Pang W, Tian J, Wang Y, Bian F, Gao Z, Condoleon A, Feng W, Zhang X, Cui N. Ji L, et al. Among authors: cui n. Diabetes Obes Metab. 2020 May;22(5):838-846. doi: 10.1111/dom.13967. Epub 2020 Feb 18. Diabetes Obes Metab. 2020. PMID: 31944546 Free PMC article. Clinical Trial.
Efficacy and Safety of Basal Insulin-Based Treatment Versus Twice-Daily Premixed Insulin After Short-Term Intensive Insulin Therapy in Patients with Type 2 Diabetes Mellitus in China: Study Protocol for a Randomized Controlled Trial (BEYOND V).
Liu J, Jiang X, Xu B, Wang G, Cui N, Zhang X, Liu J, Mu Y, Guo L. Liu J, et al. Among authors: cui n. Adv Ther. 2020 Apr;37(4):1675-1687. doi: 10.1007/s12325-020-01265-6. Epub 2020 Mar 4. Adv Ther. 2020. PMID: 32130661
Efficacy of once-daily glucagon-like peptide-1 receptor agonist lixisenatide as an add-on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual-level pooled analysis of phase III studies.
Liu F, Liu Y, Liu M, Wu G, Zhang M, Zhang X, Cui N, Yin H, Chen L. Liu F, et al. Among authors: cui n. J Diabetes Investig. 2021 Aug;12(8):1386-1394. doi: 10.1111/jdi.13504. Epub 2021 Feb 28. J Diabetes Investig. 2021. PMID: 33475222 Free PMC article. Clinical Trial.
1,261 results